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Background. The conduct of clinical trials is increasingly challenging due to greater complexity and governance requirements as
well as difficulties with recruitment and retention. Electronic Health Records for Clinical Research (EHR4CR) aims at improving
the conduct of trials by using existing routinely collected data, but little is known about stakeholder views on data availability,
information governance, and acceptable working practices.Methods. Senior figures in healthcare organisations across Europe were
provided with a description of the project and structured interviews were subsequently conducted to elicit their views. Results. 37
structured interviewees inGermany, UK, Switzerland, and France indicated strong support for the proposed EHR4CR platform. All
interviewees reported that using the platform for assessing feasibility would enhance the conduct of clinical trials and the majority
also felt it would reduce workloads. Interviewees felt the platform could enhance trial recruitment and adverse event reporting but
also felt it could raise either ethical or information governance concerns in their country. Conclusions. There was clear support for
EHR4CR and a belief that it could reduce workloads and improve the conduct and quality of trials. However data security, privacy,
and information governance issues would need to be carefully managed in the development of the platform.
1. Background
Electronic Health Records for Clinical Research (EHR4CR)
is a large private-public partnership project which involves 34
academic and private partners, including 11 academic health
provider sites across France, Germany, Poland, Switzerland,
and the United Kingdom [1]. The project aims to design
and build a robust and scalable platform to reuse data from
Electronic Health Record (EHR) systems whilst adhering to
ethical, regulatory, and data governance policies within each
of the countries of the participating sites.
The aim of the EHR4CR platform is to support the
conduct of clinical trials, specifically to (1) assist in the
assessment of trial feasibility, (2) aid patient recruitment, (3)
allow automated preloading of clinical information from a
patient’s EHR to a trial data collection form, and (4) use EHR
information in the reporting of Serious Adverse Events (SAE)
during a trial.
There are increasing challenges in the clinical trials envi-
ronment from economic pressures and regulatory demands.
The pharmaceutical industry in particular is investing more
in clinical research, year-on-year, but bringing fewer new
drugs to the market. Around 57% of pharma research costs
are spent on the conduct of clinical trials [2], and yet this
stage of drug development contains significant avoidable
costs, such as protocol amendments due to recruitment delays
[3] (costing around $0.5 million per amendment). However,
there is also a growing consensus that the use of EHRs
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can provide new and unique opportunities to develop more
efficient trial processes. Previous work has shown that use
of EHRs can improve quality assessment, epidemiological
research, and clinical trials within primary care [4], and using
EHRs can improve patient recruitment rates to trials [4–6].
However there are still few examples of where research data
are integrated with patient clinical data [7] and there are
concerns around meeting privacy, regulatory, and data gov-
ernance requirements when using EHRs for research [8, 9].
To better understand how different technical approaches
would be seen in terms of ethical, regulatory, and data gov-
ernance attitudes across the different countries we decided to
conduct a series of structured interviews with senior figures
in healthcare organisations across Europe (including man-
agers and information governance staff, academics, clinical
opinion leaders, ethicists, and research funders).
2. Methods
Materials for the conduct of structured interviews with
senior figures in healthcare organisations across Europe
(including managers and information governance staff, aca-
demics, clinical opinion leaders, ethicists, and research fun-
ders) were developed based on detailed interviews con-
ducted in a pilot study in Glasgow, Scotland [10]. The
final interview schedule consisted of a series of ques-
tions relating to different aspects of the project which the
interviewee responded by using a five-point Likert scale
(Strongly Agree/Agree/Neither/Disagree/Strongly Disagree)
and a number of free text responses for other issues not raised
within the set questions.
The principal investigator at each of the pilot sites par-
ticipating in EHR4CR was contacted and asked to conduct
interviews for the stakeholder engagement survey with key
people in their own geographic area using a snowball sam-
pling technique [11]. The selection of participants was left
to the discretion of each site so they could best utilise their
local knowledge and networks, although different categories
of interviewee were defined. Potential interviewees were
contacted and asked to participate and if they agreed a
time was set either for a face-to-face or telephone interview,
dependent on the interviewees’ preferences. The interviews
were conducted by senior members of project staff (usually
the PI) in the second half of 2012 and the first half of 2013.
The interviewees were provided with a description of the
project and structured interviews were conducted initially
focusing on the four project objectives (trial feasibility,
facilitating recruitment, facilitating clinical trial delivery, and
reporting of adverse drug events). Within each objective a
series of scenarios as illustrated below were presented and
related questions posed.
3. Trial Feasibility
Access to patient data is required to inform trial design
and trial feasibility assessment and so information and
governance approval would be required for the generic
process rather than a specific trial. A clinical research sponsor
would be interested in examining the prevalence or incidence
of a disease or the rate of clinical outcomes of interest.
By comparing a defined set of inclusion/exclusion criteria
against data held at a number of centres this would help
improve trial design, in particular by estimating the likely
number of patients who would match the eligibility criteria,
thereby allowing a more accurate prediction of recruitment
rates per site.
The first part of the interview questionnaire presented
four different options, as Scenarios A–D, for the kind of
information that could be extracted from a hospital EHR
system and returned to the research sponsor.
Scenario A. Only the total number or percentage of eligible
patients meeting all criteria is returned to the research
sponsor.
Scenario B.The total number or percentage of eligible patients
meeting each individual criterion is returned to the research
sponsor.
Scenario C. Total number or percentage of eligible patients
meeting each criterion is returned to a third party to work on
behalf of the research sponsor.
ScenarioD. Deidentified individual patient records relating to
the eligibility criteria are returned to the research sponsor.
A set of questions were posed regarding the acceptability
of each of the four scenarios, from different ethical and
governance perspectives.
4. Facilitating Recruitment
Once a clinical trial protocol has been finalised, the EHR4CR
platform could transmit the patient eligibility criteria elec-
tronically to each participating hospital or another partici-
pating organisation, for example, community mental health
team. This part of the interview questionnaire explored the
acceptability of using these electronic criteria to support a
hospital to identify and contact potentially eligible patients
(Scenario E).
Scenario E. Routinely collected patient data could be used
to facilitate the identification of potentially eligible recruits
for the trial at a centre, given that all relevant permissions
are in place. The study inclusion/exclusion criteria would be
provided and run on behalf of the investigator against the
local database to extract a list of potentially eligible patients.
The local investigator could select individuals from the list
as appropriate and generate letters of invitation to participate
in the trial to the patients. No individual patient level data
would be returned to the organisation conducting the clinical
research prior to patient consent.
5. Facilitating Clinical Trial Execution
Thenext two scenarios related to information onpatientswho
have been recruited into the trial and provided full informed
consent for the use of their electronic health record.
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Scenario F. Data is extracted from the electronic health record
into the trial database to facilitate trial conduct. There would
be an option to allow the investigator to approve each data
transfer.
Scenario G. Data collected specifically for the trial is added to
the patient’s electronic health record.
Interviewees were asked to comment on the acceptability
of each of these two scenarios, which are not mutually
exclusive.
6. Reporting of Adverse Drug Events
The final four scenarios focused on the electronic extraction
and communication of data about a serious adverse event
occurring during a clinical trial. These scenarios portrayed
different aggregation levels of patient data.
Scenario H. Individual patient records relating to adverse
event data and associated clinical and prescribing data are
returned to the organisation conducting the clinical research.
Scenario I. Individual patient records relating to adverse event
data and associated clinical and prescribing data are returned
to a local clinician to support the completion and submission
of each ADE to the marketing authority and the regulatory
agency, as appropriate.
Scenario J. Automated extraction of periodic aggregated
summary information on adverse events extracted from
electronic records and reported to the marketing authority
and the regulatory agency, as appropriate.
A final scenario (Scenario K) describing the use of an
existing national dataset of deidentified patient data was
described and interviewee responses to related questions
were collected.
7. Motivations and Threats
In addition, a series of questions were posed relating to
(a) motivating factors for a hospital/academic institution to
participate in trials using the proposed EHR4CR platform
and (b) threats and challenges to the success of an EHR4CR
platform to support trials. Finally, interviewees were asked to
give their overall impression of the EHR4CR project.
Responses from each interviewee were recorded using
a standardised form relating to the specific questions asked
within the interview. These were then anonymised and
returned to the Robertson Centre for Biostatistics, University
of Glasgow, where they were entered into a study database.
The individual identities of each interviewee were not
recorded. Each interviewee could be categorised by country
and their job role, although some may have had multiple
roles (e.g., clinical and academic). Individual responses to
set questions were reported using the frequency for each
response category. Free text responses were reviewed but
proved not to be very helpful with no additional information
taken from these.
Table 1: Country and job category of respondents.
Number of
respondents 𝑛 = 37
Country
UK 11
Germany 16
Switzerland 8
France 2
Job 𝐶𝑎𝑡𝑒𝑔𝑜𝑟𝑦∗
Healthcare organisation, general
management 3
Healthcare organisation, research
management 5
Healthcare organisation, information
governance officer 3
Senior clinical researcher/CTU director 7
Senior informatics staff 4
Healthcare service provider 10
National policy makers 3
National opinion leaders 4
Patient association lead 3
Ethics committee representative 3
∗Participants may be in more than one category.
8. Results
There were a total of 37 structured interviews conducted by
the leads at 7 different pilot sites for EHR4CR in Germany,
the UK, Switzerland, and France with the breakdown of
personnel type interviewed and their location shown in
Table 1. The leads at the centres reported conducting a mix
of telephone and face-to-face interviews with each lasting
between 60 to 90 minutes, although data on format and
timing were not collected.
8.1. Trial Feasibility. Interviewees were unanimous that an
EHR4CR platform approach to assessing feasibility would
enhance the conduct of clinical trials and a clear majority of
responders indicated that they anticipated that this approach
would reduce workloads in the assessment of clinical trial
feasibility for clinical and research staff at the participating
centres (24% Strongly Agree and 47% Agree).
Themajority of respondents reported that prior informed
consent would not be required (81%), their institution
would approve data transfer (81%), and there would be no
ethics/information governance concerns (74%) for the return
of a single aggregated number of eligible patients as outlined
in Scenario A (see Table 2). Scenario B, which suggested
returning aggregated numbers for each criterion, had slightly
lower levels of support: prior informed consent not needed
(70%), institution approved (70%), andno ethics/information
governance concerns (65%).
The scenarios suggesting the return of anonymous data to
a third party (Scenario C) or the research sponsor (Scenario
D) had markedly different results. The respondents reported
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Table 2: Use of the EHR4CR platform for trial feasibility.
Scenario A B C D
Do you think that data transfer would require previous informed consent by
patients for the use of their data in this manner?
Yes 7 (19) 10 (27) 25 (68) 29 (78)
No 30 (81) 26 (70) 8 (22) 5 (14)
Do not know 0 1 (3) 3 (8) 3 (8)
Do you think that data transfer would be approved by your institution (or an
institution in your country if you are not based in a healthcare institution)/by
an ethics committee in your country?
Yes 30 (81) 26 (70) 16 (43) 12 (32)
No 3 (8) 5 (14) 9 (24) 15 (41)
DK 1 (3) 2 (5) 8 (22) 6 (16)
Do you think that the transfer of these data would create ethical/information
governance concerns at your institution (or an institution in your country if
you are not based in a healthcare institution)?
Yes 7 (21) 7 (21) 22 (65) 29 (85)
No 25 (74) 22 (65) 7 (21) 2 (6)
DK 1 (3) 4 (12) 4 (12) 2 (6)
Strongly Agree Agree Neither Disagree Strongly Disagree
Indicate your agreement/disagreement with the statement that “this approach
to facilitating feasibility assessment would enhance the conduct of clinical
trials.”
0 3 (100) 0 0 0
Indicate your agreement/disagreement with the statement that “providing
data to an organisation conducting clinical research or trusted third party in
such an automated manner would reduce workloads and save time of
healthcare institution employees.”
8 (24) 16 (47) 6 (18) 4 (12) 0
Scenario A: total number of patients meeting all criteria only returned to sponsor.
Scenario B: number of patients meeting each criterion returned to sponsor.
Scenario C: number of patients meeting each criterion returned to 3rd party.
Scenario D: deidentified patient records meeting criteria returned to sponsor.
that prior informed consent would be needed (68%), less than
half felt their institution would approve data transfer (43%),
and there would be ethics/information governance concerns
(65%) using a third party to host data. Returning data to
the research sponsor would need prior informed consent
(78%), less than half felt their institution would approve data
transfer (41%), and the vast majority suggested there would
be ethics/information governance concerns (85%).
8.2. Trial Recruitment. The majority of respondents (70%)
thought that using EHR4CR for recruitment to trials would
be approved by healthcare organisations in their country
and that these approaches would also enhance the conduct
of trials (67%) (see Table 3). However, approximately 50%
of responders thought that using EHR4CR for recruitment
would create either ethics or information governance con-
cerns in their country and would require prior informed
consent (51%) and prior regulatory approval (57%).
8.3. Facilitating Trial Execution. The respondents reported
that using EHR4CR to extract data from the patient’s elec-
tronic records to the trial dataset would be approved by
healthcare organisations in their country (70%) and would
not raise ethics/information governance concerns (71%) (see
Table 4). There was less support for the transfer of trial data
back to the patient’s record: only 49% thought it would be
approved by their institution, whilst 47% thought it would
raise ethics/information governance concerns. Respondents
suggested the transfer of trial specific data into electronic
health records could lead to some concerns for treating
physicians (65%) but this could be reduced by holding this
data separately (59%).
8.4. Adverse Event Reporting. Using EHR4CR to facilitate
adverse event reporting was widely accepted as enhancing
trials (see Table 5). Although only 50% were confident that
this would receive ethical approval for return of all data
to the research sponsor (Scenario H), this increased if data
were dealt with by a local clinician (Scenario I, 70%) or
to the regulatory authority (Scenario J, 59%). Half (50%)
of respondents thought returning adverse event reporting
data to the research sponsor would raise ethics/information
governance concerns, but this reduced to a quarter (24%) if
returned to a local clinician (24%) or a third (32%) if returned
to the regulatory authority (32%).
9. Motivations and Threats
The strongest motivating factors for future participation in
an EHR4CR platform (see Table 6) were income generation
from industry trials (Strongly Agree 16% and Agree 54%),
providing patients with faster access to novel medicines
(Strongly Agree 27% and Agree 46%), stimulus for the
development of local health information systems (Strongly
Agree 22% and Agree 51%), improved quality of healthcare
data (Strongly Agree 38% and Agree 41%), potential to use
the platform for academic studies (Strongly Agree 35% and
Agree 49%), improvement in the quality (Strongly Agree
32% and Agree 46%), and efficiency (Strongly Agree 30%
and Agree 54%) of trials. The biggest threats raised to the
success of EHR4CR were considered to be the inadequacy
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Table 3: Use of the EHR4CR platform for trial recruitment (Scenario E).
Yes No DK
Indicate whether you think that this scenario would
require previous informed consent by patients for the use
of their data by the investigator/by the healthcare team.
19 (51) 16 (41) 1 (3)
Indicate whether you think that this scenario would
require previous authorisation from data protection
authority or another external regulatory body.
21 (57) 11 (30) 4 (11)
Do you think that this scenario would be accepted by your
institution (or an institution in your country if you are not
based in a healthcare institution)/do you think, in your
opinion, that this scenario would be approved by an ethics
committee in your country?
26 (70) 6 (16) 5 (14)
Indicate your agreement/disagreement with the statement
that “this approach to facilitating patient recruitment
would enhance the conduct of clinical trials.”
Strongly
Agree
0
Agree
2 (67)
Neither
1 (33)
Disagree
0
Strongly Disagree
0
Do you think that this scenario would create
ethical/information governance concerns at your
institution (or an institution in your country if you are not
based in a health care institution)?
Yes
17 (50)
No
16 (47)
DK
1 (3)
Indicate your agreement/disagreement with the statement
that “this approach to facilitating patient recruitment
would reduce workloads and save time of healthcare
institution employees.”
Strongly
Agree
11 (32)
Agree
18 (53)
Neither
4 (12)
Disagree
0
Strongly Disagree
0
of local health information systems (Strongly Agree 16% and
Agree 43%); missing key data items (Strongly Agree 16% and
Agree 46%); the cost of upgrading local system environments
(Strongly Agree 32% and Agree 27%), and ethical (Strongly
Agree 8% and Agree 49%), data protection (Strongly Agree
11% and Agree 46%), and information governance (Strongly
Agree 14% and Agree 51%) concerns.
10. Discussion
The overwhelming message from stakeholder engagement
was the positive support for the proposed EHR4CR platform
to enhance the conduct of feasibility assessments and the
recruitment of study subjects and thereby to improve the
conduct of clinical trials. However respondents highlighted
that the platform may raise ethical and governance concerns
in all areas and failing to meet these requirements would
constitute major threats to the project. The requirement for
regulatory and institutional support within the proposed
feasibility scenarios suggested strongly that patient data
should not be transferred outside the host institution and also
that patients should be given an opportunity to opt out of use
of their EHR.
Stakeholder support for the project was shown through
agreement that it would improve the local quality of care
offered to patients, could improve local health systems,
and would help patients get access to new medications
faster. Increased participation for local centres in trials and
additional financial benefits associated with this were also
highlighted, although few stakeholders suggested these as
reasons to participate.
The EHR4CR stakeholder engagement raised many
important issues about governance, privacy, and data man-
agement and data standards. The development of the
EHR4CR project and how it addressed these barriers and
challenges will provide information to influence future devel-
opments in big healthcare databases. With the ultimate
goal of improving clinical trials in the European Union,
the project provides a unique opportunity to coordinate
important stakeholders’ efforts to create new clinical trials
environments.
11. Strengths and Limitations of the Work
Although this survey was targeted at informing the design
and governance of the EHR4CR platform, the scenarios
and the interview questions were posed in a generic form
which relates to the use of hospitals electronic health record
system to support the design, recruitment, and conduct of
clinical trials. Interviewees therefore did not need to have
a detailed understanding of the project or its particular
technical implementation in order to respond to the survey.
The seniority of the individuals invited for interview
and the length of the interview (often between 60 and 70
minutes) will have placed practical limits on the number
of participants per country, and the number of countries
which could be included in this survey. The interviews were
arranged and conducted by senior academics whowere aware
of the potential risk of bias and each deliberately sought to
invite interview senior individuals who were not otherwise
connected with the project or with the partner organisations
in the consortiumbutwould be important decisionmakers or
decision influences in the wider acceptability of the proposed
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Table 4: Use of the EHR4CR platform for trial execution.
Scenario F G
Do you think that this scenario would be accepted by
your institution (or an institution in your country if you
are not based in a healthcare institution)/do you think
that this scenario would be approved by an ethics
committee in your country?
Yes
No
DK
26 (70)
4 (11)
5 (14)
18 (49)
10 (27)
5 (14)
Indicate your agreement/disagreement with the
statement that “this approach to facilitating trial
conduct would enhance the quality of clinical trials.”
Strongly
Agree 0 1 (33)
Agree 1 (33) 0
Neither 2 (67) 0
Disagree 0 2 (67)
Strongly
Disagree 0 0
Do you think that this scenario would create
ethical/information governance concerns at your
institution (or an institution in your country if you are
not based in a healthcare institution)?
Yes
No
DK
8 (24)
24 (71)
1 (3)
16 (47)
14 (41)
2 (6)
Indicate how much you would support the statement
that “extraction of data automatically from the
electronic patient record into a trial database would
reduce workloads and save time of healthcare
institution employees.”
Strongly
Agree
19 (56)
Agree
8 (24)
Neither
3 (9)
Disagree
2 (6)
Strongly Disagree
0
Yes No DK
Do you think that this scenario could create concerns
that the additional information might be
misunderstood by other physicians treating the patient
due to unfamiliar measurements or measurements
obtained by unfamiliar methods?
24 (65) 9 (24) 1 (3)
Do you think that this scenario would create fewer
concerns if the additional information was separated
from the usual patient record?
22 (59) 8 (22) 4 (11)
Scenario F: extraction of data from the patient record.
Scenario G: transfer of trial specific data to the patient’s electronic record.
Table 5: Use of the EHR4CR platform for adverse event reporting.
Scenario H I J
Do you think that this scenario would be accepted by your institution (or
an institution in your country if you are not based in a healthcare
institution)?/do you think that this scenario would be approved by an
ethics committee in your country?
Yes
No
DK
19 (51)
9 (24)
7 (19)
26 (70)
4 (11)
5 (14)
22 (59)
4 (11)
7 (19)
Do you think that this scenario would create ethical/information
governance concerns at your institution (or an institution in your country
if you are not based in a health care institution)?
Yes 17 (50) 8 (24) 12 (32)
No 16 (47) 22 (65) 21 (57)
DK 0 3 (9) 2 (5)
Indicate your agreement/disagreement with the statement that
“accumulating adverse event reports in this manner will significantly
improve the reporting of adverse drug reactions during clinical
trials”/indicate your agreement/disagreement with the statement that “this
approach to facilitating adverse event reporting would enhance the
evaluation of the safety of medicines.”
Strongly Agree 7 (19) 15 (41) 8 (22)
Agree 18 (49) 16 (43) 17 (46)
Neither 10 (27) 4 (11) 7 (19)
Disagree 1 (3) 0 4 (11)
Strongly
Disagree 1 (3) 1 (3) 0
Indicate whether you think that this scenario would require previous
informed consent by patients for the use of their data.
Yes 17 (46) 12 (32)
No 15 (41) 21 (57)
DK 3 (8) 2 (5)
Scenario H: individual patient level data on adverse events returned to organisation conducting research.
Scenario I: individual patient level data on adverse events returned to local clinician to prepare report for regulatory authorities.
Scenario J: periodic aggregated data on adverse events reported turned to regulatory authorities.
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Table 6: Motivators and threats for participation in EHR4CR.
Use of existing national datasets of deidentified data
Do you think that out-licensing from your institution (or from an
institution in your country if you are not based in a healthcare
institution) of a large body of detailed pseudoanonymised
longitudinal secondary care (hospital) data to an organisation
conducting research into postmarketing drug safety would:
Yes No Do not know
(a) Require prior patient level consent? 22 (59) 14 (38) 0
(b) Be likely to receive institutional approval? 22 (59) 6 (16) 8 (22)
(c) Raise significant ethical/information security concerns? 21 (57) 14 (38) 1 (3)
(d) Require data protection authority or another regulatory external
body approval? 26 (70) 5 (14) 4 (11)
Other aspects
Indicate your agreement/disagreement with the following as strong
motivating factors for your institution’s participation in the EHR4CR
platform (now or in the future). If you are not based in a healthcare
institution, consider these factors for an institution in your country.
Strongly Agree Agree Neither Disagree Strongly Disagree
Increased income generation from participation in more industry
trials 6 (16) 20 (54) 1 (3) 5 (14) 4 (11)
Pressure from government or institution to participate in more
pharma industry studies 6 (16) 8 (22) 8 (22) 11 (30) 3 (8)
Providing patients with faster access to new generation medicines 10 (27) 17 (46) 4 (11) 3 (8) 2 (5)
Development of local health information systems 8 (22) 19 (51) 6 (16) 1 (3) 2 (5)
Improvement of local data quality and healthcare 14 (38) 15 (41) 3 (8) 3 (8) 1 (3)
The potential to use EHR4CR platform to conduct academic studies 13 (35) 18 (49) 3 (8) 1 (3) 0
Opportunity to improve the quality of data in clinical trials 12 (32) 17 (46) 3 (8) 3 (8) 1 (3)
Opportunity to improve the efficiency of clinical trials 11 (30) 20 (54) 5 (14) 0 0
Indicate your agreement/disagreement with the following as significant threats in your institution or country to the success of EHR4CR.
Inadequate availability of key data fields in the patient record 6 (16) 16 (43) 6 (16) 6 (16) 3 (8)
Missing data in the patient record 6 (16) 17 (46) 7 (19) 7 (19) 0
Inadequacy of local health information systems 6 (16) 16 (43) 2 (5) 10 (27) 2 (5)
Cost of upgrading local systems to be compatible with EHR4CR 12 (32) 10 (27) 9 (24) 6 (16) 0
Ethical committee concerns 3 (8) 18 (49) 4 (11) 11 (30) 1 (3)
Local information governance concerns 5 (14) 19 (51) 4 (11) 9 (24) 0
Data protection authorities 4 (11) 17 (46) 5 (14) 7 (19) 2 (5)
Concerns of hospital management 2 (5) 13 (35) 8 (22) 13 (35) 1 (3)
Concerns of patients 3 (8) 11 (30) 5 (14) 16 (43) 2 (5)
Concerns of clinicians 0 13 (35) 5 (14) 16 (43) 3 (8)
approach.Nevertheless it is recognised that this surveywas by
invitation and that this sample cannot be claimed to be fully
representative of the stakeholder groups included.
12. Comparison to the Literature
There are a number of other initiatives looking to improve
clinical research through innovative uses of routine data.
The Sentinel Initiative was launched by the FDA in 2008, to
develop and implement a proactive system to track the safety
of drugs, biologics, and medical devices once they reach
the market. It uses preexisting electronic healthcare data at
collaborating institutions by running a centrally developed
computer program at each site which returns summary
results to the organising centre [12].The systemhas been used
effectively in a number of recent drug safety studies [13–15].
Other initiatives include the Observational Medical Out-
comes Partnership (OMOP) [16] and SHRINE [17], which are
public-private partnerships built upon the use and sharing
of information from existing observational databases. The
development of initiatives such as these would suggest that
the question is no longer whether but rather how clinical data
should be shared to foster innovation and support clinical
research [18].
However, it is still unknown how the process of data
sharing can become routine, how to define responsible data
sharing, which principles to establish, and how to set policies
across different countries where interpretations of clinical
and information governance may vary and where attitudes
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towards reuse of routinely collected clinical data may differ.
The EHR4CR project may be one of the milestones on the
road ahead.
13. Conclusions
There was clear support for the overall objectives of EHR4CR
and a belief that a well-developed EHR4CR platform would
reduce workloads and improve the conduct and quality
of trials. However, the interviewees did raise some ethical
and information governance concerns and threats to the
potential success of an EHR4CR platform including that only
aggregated data should be reported for trial feasibility, that
prior ethics approval may be required for use of patient’s
EHR for recruitment, and that the combination of trial data
with patient EHR could generate new issues and concerns.
This study has helped guide the development of the EHR4CR
informatics platform and highlight areas where there is a
need to clarify and emphasise data security, privacy, and
information governance issues in the roll-out of the platform.
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